Sensorion Receives Approval for SENS-401 Phase 2 Clinical Trial

The randomized, double-blind, placebo-controlled Phase 2 study will be conducted across 50 sites in Europe, the US, Canada, Israel, and Turkey, and enroll approximately 260 patients.